UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045542
Receipt number R000051999
Scientific Title Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance
Date of disclosure of the study information 2021/09/22
Last modified on 2021/09/22 16:02:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease

Acronym

Study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease

Scientific Title

Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance

Scientific Title:Acronym

Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance

Region

Japan


Condition

Condition

Mycobacterium avium complex pulmonary disease

Classification by specialty

Medicine in general Pneumology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the relationship between the effects of multidrug chemotherapy for Mycobacterium avium complex pulmonary disease and long-term prognosis, and to search for useful prognostic predictors.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

1)Relationship between the outcomes of multidrug chemotherapy and long-term survival prognosis
2)Search for useful prognostic predictors

Key secondary outcomes

Evaluation as prognostic factors the following:
1) clinical characteristics
2) chest radiographic findings
3) results of sputum smear-culture examinations for acid-fast bacteria, and serobar
4) results of blood examinations (especially serum antibodies against acid-fast bacteria)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients with Mycobacterium avium complex pulmonary disease met the criteria advocated by the American Thoracic Society 1997
2)Patients who can visit the hospital regularly for 5 years or more
3)Signed agreement to participate in the study

Key exclusion criteria

1)Patients known to be seropositive for human immunodeficiency virus
2)Judged inadequate to participate in the study by their physicians

Target sample size

41


Research contact person

Name of lead principal investigator

1st name Ryoji
Middle name
Last name Maekura

Organization

National Hospital Organization Osaka Toneyama Medical Center

Division name

Department of Respiratory Medicine

Zip code

560-8552

Address

5-1-1 Toneyama, Toyonaka, Osaka, Japan.

TEL

06-6853-2001

Email

mae.ryoji@gmail.com


Public contact

Name of contact person

1st name Ryoji
Middle name
Last name Maekura

Organization

Graduate School of Medical Safety Management, Jikei University of Health Care Sciences

Division name

Graduate school

Zip code

532-0003

Address

1-2-8 Miyahara, Yodogawa-ku, Osaka, Japan

TEL

06-6150-1336

Homepage URL


Email

mae.ryoji@gmail.com


Sponsor or person

Institute

National Hospital Organization Osaka Toneyama Medical Center

Institute

Department

Personal name



Funding Source

Organization

MHLW (Japan)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Osaka Toneyama Medical Center

Address

5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan

Tel

06-6853-2001

Email

410-chiken@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

独立行政法人国立病院機構大阪刀根山医療センター(大阪府)


Other administrative information

Date of disclosure of the study information

2021 Year 09 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

94

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 05 Month 10 Day

Date of IRB

2004 Year 05 Month 21 Day

Anticipated trial start date

2004 Year 05 Month 21 Day

Last follow-up date

2020 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

1)Relationship between the outcomes of multidrug chemotherapy and long-term survival prognosis
2)Search for useful prognostic predictors
Evaluation as prognostic factors the following:
1) clinical characteristics
2) chest radiographic findings
3) results of sputum smear-culture examinations for acid-fast bacteria
4) results of blood examinations (especially serum antibodies against acid-fast bacteria)


Management information

Registered date

2021 Year 09 Month 22 Day

Last modified on

2021 Year 09 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051999


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name